A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE SRL
Via Sette Santi, 1 50131 - Firenze (Firenze) Phone +39 055 56801 Fax +39 055 582771
Via Sette Santi, 1 50131 - Firenze (Firenze) Telefono +39 055 56801 Fax +39 055 582771
Everyday we put our values into action. 4 values, which have given life to Menarini and shaped its history.
Menarini is investing in advanced science and technology to develop a pipeline of new products that make a difference to the lives of patients affected by serious conditions.
MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
Our dedicated Corporate Business Development team is committed to assess and explore innovative new opportunities.
Donations of backpacks and cases for school, distribution of meals and medicines, promotion of sport, support for pregnant women and much more: being responsible for Menarini means transforming good intentions into concrete efforts. By helping others, we want to contribute to improve the world around us, starting with us.
What does it really make Menarini unique? The diversity and authenticity of our key resource - the People. Our cultural diversity helps us to drive innovation, adapt to business changes, face challenges, inspire ideas and develop our growth.
Menarini employees make all the difference, every day.
Ogni giorno mettiamo in pratica i nostri valori. 4 valori, che hanno dato vita a Menarini e ne hanno forgiato la storia.
Menarini investe continuamente nella scienza e nelle tecnologie all'avanguardia per lo sviluppo di una pipeline di nuovi prodotti che facciano la differenza nella vita dei pazienti affetti da gravi patologie.
Menarini è un’azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un’eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development è impegnato a valutare ed esplorare nuove opportunità innovative.
Dalla distribuzione di pasti e medicinali, dai kit per andare a scuola alla promozione dello sport all'aiuto per le donne in gravidanza: essere responsabili, per noi di Menarini, significa tradurre le buone intenzioni in sforzi concreti. Aiutando gli altri diamo il nostro contributo a migliorare il mondo che ci circonda, a partire da noi.
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.
Chi lavora in Menarini fa la differenza, ogni giorno.
Blood cancers can be difficult to diagnose. One is Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and clinically aggressive hematologic malignancy.
Although BPDCN is mostly diagnosed in elderly patients, it may occur at any age, with men three times more likely to be affected by BPDCN than women.1,2 With an estimate of just 0.44% of hematologic neoplasms annually – equivalent to roughly 700 cases in the United States and 1000 cases in Europe, BPDCN remains under-recognized.1,3
BPDCN can manifest as an unusual skin lesion, which potentially means that a person experiencing BPDCN will present to a dermatologist before they see a hematologist-oncologist. Its variable dermatologic and hematologic manifestation, compounded by its similarity to other blood cancers, has contributed to its frequent misdiagnosis and very poor prognosis.
Despite an initial response to treatment, BPDCN remains aggressive and associated with a dismal prognosis.1,4,5 Historically, the average overall survival rate after diagnosis is just 8 to 14 months.5,6 This highlights the urgent need to raise awareness of the disease to ensure proper and earlier diagnosis.
We at Menarini Group are proud to actively support Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Disease Awareness Day (#BPDCNday) as part of our unwavering commitment to make a difference in the lives of patients with cancer.
Accurate and timely diagnosis may be key to fighting back against BPDCN. Currently, diagnosis may be delayed. People with this blood cancer frequently first present to a dermatologist with a skin lesion – which may have a strong resemblance to other malignancies. This may contribute to misdiagnoses and increase the risk for patients.7,8
Frequently, the disease presents with both dermatologic and hematologic manifestations. As a consequence, a joint effort between dermatologists, pathologists, and hematologist-oncologists is essential for the diagnosis and care of BPDCN patients.
Biopsies of not only skin but also bone marrow and secondary sites are critical for diagnosis.1,7,9-13 Recently, a specific protein – CD123 – which is highly expressed on BPDCN cells - has been confirmed to play an important role in improving diagnosis. Pathologists use the marker triad of CD123, CD4 and CD56 to confirm the diagnosis of BPDCN.*,1,5,7,14
23rd January 2022, is the third annual #BPDCNday since the condition received its own classification from the World Health Organization (WHO).
The date—the 1st month and 23rd day of the year—reflects the importance of the CD123 biomarker in the diagnosis and therapeutic target for BPDCN.
With #BPDCNday, our aim is to raise awareness in the medical community and unite patients and healthcare professionals in the fight against this disease. We hope you will join us in supporting patients and families affected by BPDCN around the world.
We at Menarini Group believe that working together can make real changes. We also know that the medical professionals and patients dealing with BPDCN are committed to the fight against BPDCN.
Learn more at: www.bpdcninfo.eu
Video
*BPDCN can include other markers, such as TCL1, TCF4, and CD303 (BDCA2).7,14
References
Discover our stories from all over the world
Menarini � un�azienda privata completamente integrata con una lunga storia di collaborazioni di successo in tutto il Mondo. In Menarini abbiamo una conoscenza ed esperienza consolidata frutto della nostra capacità di Ricerca & Sviluppo nelle aree terapeutiche chiave, accompagnate da un�eccellente presenza capillare in tutto il Mondo.
Il nostro Team dedicato di Business Development � impegnato a valutare ed esplorare nuove opportunità innovative.
Scopri le nostre storie da tutto il mondo
Che cosa rende davvero Menarini unica? La diversità ed autenticità del nostro valore più importante - le Persone. La nostra diversità culturale ci aiuta a guidare l'innovazione, ad adattarci ai cambiamenti di mercato, ad affrontare le sfide, ad ispirare idee e a promuovere la nostra crescita.